T-Cypher Bio

T-Cypher Bio

Private
OxfordHealthcare & Life Scienceshttps://tcypherbio.com/

Last Round

Seed

Feb 25, 2021

Total Funding Raised

$42.3M

Company Overview

T-Cypher Bio is a biotechnology company that develops a pipeline of novel, T-cell receptor (TCR)-based therapeutics for solid tumours, autoimmune, and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Infrastructure

Keywords

TCR therapeuticsTCR discoveryAI drug discoverytarget discoveryimmunotherapycell therapyTCR discovery platformTCRsolid tumor therapeuticsautoimmune disease therapeuticsT-cell receptorcomputational biologytherapeutic pipelinehigh-throughput discoverymicrofluidics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

T-Cypher Bio Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

T-Cypher Bio Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
SeedFeb 25, 2021
Series AFeb 25, 2021

Key People

Founding team and executive leadership

Sarah Leonard

Interim Chief Executive Officer

Executive Team

T-Cypher Bio Investors

Notable investors and investment history

InvestorRounds
Oxford Science EnterprisesSeries A, Seed
University of OxfordSeries A, Seed
Borealis VenturesSeries A, Seed
Rio Tinto VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 27, 2024

    Grew 20% QoQ, from 25 to 30 employees.

  • Apr 12, 2024

    Grew 30% QoQ, from 23 to 30 employees.

T-Cypher Bio Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

T-Cypher Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about T-Cypher Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range43
Year Founded2020
Last FundingFeb 25, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.